Testing therapies that alter the tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC)
Return to Listing
Enabled research team to investigate the potential of immune therapy to halt pancreatic cancer progression when used in combination with repurposed FDA-approved Nox inhibitors and a novel immune cell homing molecule produced at MCW
Completed a series of studies to improve detection of tumor reactive lymphocytes in pancreatic cancer. These approaches include detection of T cells within the central immune tissues (bone marrow), peripheral immune tissues (liver, spleen) and pancreatic tumor parenchyma. The team discovered that recombinant chemokines continue to have powerful use as a biologic therapy, with effects on tumor cells and tumor reactive T cells. While these results have been largely in preclinical animal models, they should be readily translatable to the clinic
8701 W Watertown Plank Road, Milwaukee, WI 53226-0509 (414) 955-4350
Contact Us
Subscribe
Governance and Reporting
Funding Opportunities
Maps & Directions
©2021 MEDICAL COLLEGE OF WISCONSIN. ALL RIGHTS RESERVED | MCW.EDU | TERMS & PRIVACY | NON-DISCRIMINATION NOTICE